Pathogenicity and drug resistance in Candida albicans and other yeast species: a review by Mishra, Nagendra Nath et al.
PATHOGENICITY AND DRUG RESISTANCE
IN CANDIDA ALBICANS AND OTHER YEAST SPECIES
A REVIEW
NAGENDRA NATH MISHRA1*, TULIKA PRASAD2, NEERAJ SHARMA3,
ANURAG PAYASI1, RAJENDRA PRASAD2, DWIJENDRA K. GUPTA4
and RANDHIR SINGH1
1Department of Biotechnology, Seth J. M. Institute of Engineering and Technology,
Radaur-135133, Yamuna Nagar, India
2Membrane Biology Labpratpry, School of Life sciences, Jawaharlal Nehru University,
New Delhi-110067, India
3Gene Regulation Laboratory, National Institute of Immunology,
New Delhi-110067, India
4Department of Biochemistry, Allahabad University, Allahabad-211002, India
(Received: 20 April 2007; accepted: 30 April 2007)
Pathogenic yeasts from the genus Candida can cause serious infection in hu-
mans particularly, in immunocompromised patients and are now recognized as major
agents of hospital acquired (nosocomial) infections. In the recent years, there has been
a marked increase in the incidence of treatment failures in candidiasis patients receiv-
ing long-term antifungal therapy, which has posed a serious problem in its successful
use in chemotherapy. Candida cells acquire drug resistance (MDR) during the course
of the treatment. The mechanisms of resistance to azole antifungal agents have been
elucidated in Candida species and can be mainly categorized as (i) changes in the cell
wall or plasma membrane, which lead to impaired drug (azole) uptake; (ii) alterations
in the affinity of the drug target Erg11p (lanosterol 14µ-demethylase) especially to
azoles or in the cellular content of Erg11p due to target site mutation or overexpression
of the ERG11 gene; and (iii) the efflux of drugs mediated by membrane transport pro-
teins belonging to the ATP-binding cassette (ABC) transporters, namely CDR1 and
CDR2 or to the major facilitator superfamily (MFS) transporter, CaMDR1. Many such
manifestations are associated with the formation of Candida biofilms including those
occurring on devices like indwelling intravascular catheters. Biofilm-associated
Candida show uniform resistance to a wide spectrum of antifungal drugs. A combina-
tion of different resistance mechanisms is responsible for drug resistance in clinical
isolates of Candida species.
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Introduction
The apparent exaltation of fungal infections may be explained by the in-
creasing number of immunocompromised patients [1]. Having emerged as the ma-
jor causes of morbidity and mortality in immunocompromised hosts, Candida
spp., mainly Candida albicans and to a smaller extent, also other non-albicans
species (C. dubliniensis, C. glabarata, C. guilliermondii, C. krusei, C. lusitaniae,
C. parapsilosis, C. tropicalis, etc.) represent the major group of yeast species re-
covered from infected individuals [2]. Incidence of C. albicans cells acquiring re-
sistance to antifungals like azoles has increased considerably, causing serious
problems in successful chemotherapy. Both C. albicans as well as non-albicans
species have developed a variety of mechanisms to combat resistance to anti-
fungal drugs [3].
Pathogenesis and candidiasis
In the last decades, the incidence of fungal infections by C. albicans and
other related human opportunistic yeast species has increased dramatically due to
the rise in the number of immunocompromised patients. Several Candida spp., es-
pecially C. albicans, normally inhabit the oral cavity, respiratory, intestinal tracts
and vaginal cavity of humans and animals. Colonization with C. albicans can lead
to systemic infection when the host presents risk factors. Predisposing factors for
candidiasis (Table I) include immunosuppressive and cytotoxic therapies, treat-
ment with broad spectrum antibiotics, AIDS, diabetes, drug abuse, use of catheters
and indwelling devices, etc. Depending on the underlying host defects, the micro-
organism may cause a wide variety of infections ranging from mucosal to life
threatening disseminated candidiasis [2]. Therefore, development of candidiasis
depends on a delicate balance between the fungi and the host’s immune status
which determines the commensal or parasitic relationship.
Interactions between C. albicans cells and mammalian host tissues are
highly complex. Candida infections arise as a sequence of time-scaled steps. First,
adhesion to an epithelial surface is required to initiate the colonization of the ac-
tual surface. Penetration into the epithelial surfaces is the limit of the infectious
process in most cases, leading to the establishment of a superficial candidiasis;
normally the fungi are incapable of further invasion into the immunologically in-
tact host. When fungi reach the bloodstream, they must face the blood-borne cellu-
lar defense system. Finally to cause invasive infections Candida cells should be
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able to penetrate the endothelial surfaces and invade the tissues. Different factors
of host and fungal cells may have a major role at each step of the infectious path-
way, although no component has yet been found to be absolutely essential [4].
From clinical data, it appears that both antibody- and cell-mediated immune re-
sponse contributes to host protection against candidiasis [5, 6].
C. albicans pathogenicity depends, in addition to the immune status of the
host, on a complex set of microorganism-related putative virulence factors. These
Acta Microbiologica et Immunologica Hungarica 54, 2007
PATHOGENICITY AND DRUG RESISTANCE IN YEAST SPECIES 203
Table I
Incidence of candidiasis, locations, symptoms and predisposing factors
Type Location Symptoms Predisposing factors
Superficial
Oral thrush
Stomatitis
Leukoplakia
Vulvo-vaginal
Candida onychia
Systemic
Oesophageal
Gastric
Candidiasis of lower
respiratory tract
Candiduria
Candida endocarditis
Candida meningitis
Candida arthritis
Disseminated
Oropharynx
Palate
Inner cheek surface
Vagina, perinal area
Brown, greenish dis-
coloration of nails
Oesophagus
Stomach
Bronchi, lungs
Kidney, urinary tract
Heart, aortic and mitral
valve
Granulomas of
ventricle, lesions
Necrosis of cartilages,
abscess formation
Eye, skin, blood
White lesions resembling
milk curd on the surface of
throat, tongue, gum linings
Erythema, oedema of palate
Chronic lesions
White discharge, intense
erythema
Swollen, painful inflamma-
tion of nail and nail folds
Dysphagia, retrosternal
pain
Lesions, vomiting
Lesions
Microabscesses
dissemination
in urinary tract
Intracardiac vegetation
blocking blood vessels
Microabscess,
headaches, lesions
Swelling, painful
joints
Old age, infancy
Old age
Tobacco smoking
Pregnancy, diabetes
Occupational hazards
(fruit canners)
Fatally ill patients,
AIDS patients
Pre-existing lesions,
parenteral nutrition
Aspiration
Diabetes, old age,
drug abuse
Cardio pulmonary
bypass, open heart surgery
No particular factor
Intra-articular steroid
injection, trauma, cancer
patients
Leukaemic patients, burn
victims, latrogenic factors
include the secretion of hydrolytic enzymes, antigenic variability, adhesion to host
cells and tissues as well as to inert substrates, dimorphic transition (yeast-to-
hypha), phenotypic switching or the ability to switch among different cell pheno-
types and modulation of the host’s immune response [7–12]. Expression of most
virulence factors is regulated in vitro by environmental parameters and in vivo it
depends on the stage of infection and varies also according to host species or tis-
sues.
It is generally accepted that dimorphism (the ability to grow either as bud-
ding yeast or as a filamentous form or hypha) is a virulence trait per se, and is
coregulated with other virulence factors associated with the cellular morphology,
too [13, 14]. In addition to the yeast-hypha transition, C. albicans may undergo
also another type of morphological change called phenotypic switching, involving
the spontaneous and reversible generation of different morphological and physio-
logical states expressing different patterns of pathogenicity-related traits (viru-
lence factors, antigenicity and resistance to antifungal drugs) readily observed by
the morphology of the colonies [11, 15]. Both processes, dimorphic transition and
switching, confer on C. albicans the ability to generate variants allowing a better
selective adaptation to changing environmental conditions, and particularly to
evade the host’s immune system.
As with many pathogenic microorganisms, adhesion of C. albicans to the
host surface is a crucial step in the pathogenic process and a prerequisite for colo-
nization of the host’s tissues. C. albicans adhesion to host (epithelial and endothe-
lial cells, soluble factors, extracellular matrix) and inert materials implanted in the
body of the host involves multiple adherence mechanisms mediated by cell wall
components designated as adhesins [9].
A complex assortment of hydrolytic enzymes is found in culture filtrates of
C. albicans cells. Although some of the proteins present in these filtrates represent
products specifically secreted, some others may be components shed from the cell
wall, or even released from cytoplasm by spontaneous cell lysis. Several of the se-
creted proteins may be considered as virulence factors since the hydrolytic action
of these extracellular proteins affects the function and viability of the host, thus
contributing to the establishment and progress of infection [9].
Role of cell wall associated components in pathogenicity
This section includes (i) secreted proteins, mainly hydrolytic enzymes that
act on host substrates, (ii) proteins involved in adhesion to host ligands and tissues
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and (iii) the role of cell wall components as inducers or mediators of the host
immune response.
Secreted protein
Secreted hydrolytic enzymes may be considered as virulence factors
contributing to the establishment and progress of infection. Expression and
intracellular distribution depend on environmental conditions.
Secreted acid proteinase
The extracellular proteolytic activity described for C. albicans is due to
aspartyl proteinase enzymes constituting a family of enzymes (SAP: secreted
aspartyl proteinases) whose expression depends on both the yeast strain and the
environment [12, 16]. Several observations suggest a major role for Sap proteins
in the pathogenesis of candidiasis: (i) SAP are secreted by pathogenic Candida
species in vivo during infection and there is a correlation between virulence and
the level of proteinase production in both the clinical isolates and laboratory
strains of C. albicans; (ii) the enzymes are able to degrade a number of important
defensive host proteins such as immunoglobulins and complement and (iii) genet-
ically engineered strains harboring disruptions in SAP genes showed a reduced
virulence in an animal model of disseminated candidiasis. Therefore, proteinase
production appears to enhance the ability of the fungal cells to colonize and pene-
trate host tissues and to evade the host immune system.
Phospholipase
C. albicans cells exhibit phospholipase A, B and C as well as lysophospho-
lipase and lysophospholipasetransacetylase activities [16, 17]. Phospholipase ac-
tivities are considered as putative virulence factors since they are associated with
host cell membrane damage, adherence and penetration. Molecular organization
of C. albicans cell wall reveals that a scaffold of branched b-1,3-glucan serves for
the covalent attachment of other cell wall components; covalent linkages (as
disulfide bridges) between different cell wall mannoproteins (CWP) also exist and
some mannoproteins are linked to chitin [18]. Phospholipase production by
C. albicans strains therefore result in adhesion to epithelial cells and virulence in a
mouse model.
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Hemolytic factor
C. albicans exhibits hemolytic activity when cultured on glucose-enriched
blood agar; this activity is detected in intact cells, particularly in hyphae, and se-
creted also into the culture medium. This hemolytic activity, is associated to a
mannoprotein residing in its mannan moiety, and may be considered as a putative
virulence factor as it can allow iron acquisition from hemoglobin released after
lysis of host erythrocytes, thus favoring the ability to grow in the host’s serum [9].
Immunosuppressive and B-cell mitogenic protein
An immunosuppressive, B-cell mitogenic protein (ISM p43) is secreted
into the culture medium by C. albicans [10, 19]. This protein belongs to the ISM
proteins produced by other pathogens, that are virulence factors producing
immunosuppression, as a consequence of B-cell overstimulation, and is crucial for
the survival of the pathogen within the host. The immunosuppressive and B-cell
mitogenic properties of p43 are quantitatively associated with the host susceptibil-
ity to C. albicans infections.
Other secreted proteins
C. albicans cells are able to secrete into the medium, under proper inducing
conditions, also other enzymes like acid phosphatase, trehalase, glucoamylase,
esterase, lipase, hyaluronidase, chondroitin sulfatase and metallopeptidase [9, 10,
16, 20, 21]. Some of these catalytic mannoproteins are thought to be virulence fac-
tors contributing to candidal infection, particularly by the combined action with
acid proteinases and phospholipases. In addition, a variety of proteins whose pri-
mary location is the cytosol were also found incorporated into the cell wall, such
as several glycolytic proteins (GAPDH, PGK, ADH, enolase) and members of the
HSP family (HSP70, HSP90 and others HSPs). Some of these proteins may have
relevant roles in pathogenesis, either as putative adhesion factors or as modulators
of the host immune response [9, 10].
Binding proteins for host ligands
Physical interactions between C. albicans cells and the host are mediated
by active radicals on the cell wall as the cell wall is the outermost surface of the
microorganism. Potential interactions may involve host soluble proteins,
extracellular matrix proteins as well as phagocytic cells and any host cell or organ
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that can be infected by the fungus. The role of these interactions in pathogenesis is
complex, as there is a wide variety of adhesion factors and their participation in
virulence may depend on the fungal strain, type of infected host tissue and host’s
immune status.
Although cell wall components, such as chitin, glucans or lipid molecules
play some role in adhesion, protein and mannoproteins are the major mediators in
adhesion of C. albicans to the host. Adhesion at molecular level may involve dis-
tinct types of interactions between microbial and host molecules. Also, adhesion
to plastic surfaces and fungal cell surface hydrophobicity (CSH), which may play
an important role in pathogenesis, are mediated by cell wall-associated manno-
proteins. In this section we summarize the most relevant features of the candidal
adhesion [9, 10, 22–26].
Lectin-like molecules
Proteinaceous candidal adhesin might interact with glycoside receptors
(glycoprotein or glycolipid) in a lectin-like manner, as described in many bacterial
adhesion mechanisms [9, 27, 28]. This type of interaction seems to be a major
mechanism of adhesion to epithelial cells. Several lectin-like molecules have been
described in C. albicans. Binding proteins may recognize L-fucose-, N-acetyl-
galactosamine- or N-acetylglucosamine-containing glycosides, possibly in the
form of blood group antigens, which can serve as epithelial cell receptors for the
microorganism.
Binding of fungal cells to erythrocytes mediated by sugar ligands on eryth-
rocyte surface may contribute to a fungal system for iron acquisition. Fimbriae
bind directly to epithelial buccal cells and the protein moiety of the 66 kDa, a ma-
jor structural fimbrial glycoprotein appears to mediate binding to glycosphin-
golipids displayed on these cells. In addition, among several adhesins that
C. albicans utilizes for interacting with type 4 collagen, there is some lectin that
recognizes specific oligosaccharide residues at the receptor level [29]. Candida
lectin-like receptors also recognize salivary proteins, such as mucins, as well as
bacterial complex polysaccharides mediating adhesion to Streptococcal species;
such interactions may contribute to oral colonization [9, 30].
Proteins recognizing RGD-containing ligands
Candidal cell surface proteins displaying RGD (arginineglycine-aspartic
acid motif)-binding activity can be considered as integrin analogues [26, 27],
RGD motifs are present in extracellular matrix proteins, complement C3 frag-
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ments and fibrinogen, which bind to b1 and b2 mammalian integrins, hetero-
dimeric transmembrane proteins that play a major role in adhesion of mammalian
cells to the extracellular matrix (ECM).
C. albicans expresses cell surface receptors for complement C3 conversion
products: C3d-binding (complement receptor 2, CR2) and iC3b-binding (comple-
ment receptor 3, CR3) proteins [9, 26, 27]. Deposition of complement fragments
on any surface (epithelial, endothelial or plastic) would provide a potential bridge
for adhesion of C. albicans. Clumping between opsonized and non-opsonized
C. albicans cells by using CR may lead to the formation of aggregates that might
protect the fungal cell from phagocytosis. Furthermore, the C. albicans cell sur-
face can bind complement regulator factors H and FHL-1 and is able to regulate al-
ternative complement activation at its surface and to inactivate toxic complement
activation products [31].
It is well known that C. albicans exhibits an affinity for laminin, fibro-
nectin, and other ECM proteins mediated by fungal integrin-like receptors facili-
tating colonization of endothelial and epithelial surfaces [9, 26, 27]. Laminin, a
major component of the basement membrane, is recognized by several surface re-
ceptors of C. albicans. Studies of adhesion to endothelium indicated a role for
fibronectin as the most important host ligand for candidal adhesion.
Different receptors have been identified at the cell wall of both yeast and
hyphal forms. Adhesion of C. albicans to type I and type IV collagen, a compo-
nent of the basement membrane, is almost completely inhibited by fibronectin, in-
dicating that common receptors interact with both ligands and similar molecular
species have been described to bind collagen and fibronectin. Binding among fun-
gal receptors and collagen molecules may involve different types of interactions,
as RGD peptides only inhibited adhesion to type IV collagen, and a collagen
lectin-like candidal adhesion has been described [9, 29]. Several moieties from
yeast and hyphal forms were found to bind entactin, and this interaction is partially
mediated by RGD-binding sites. Besides their role in adhesion, candidal
integrin-like molecules may have additional roles in C. albicans physiology, as
described for Intp, an integrin-like receptor involved in adhesion, dimorphic
yeast-to-hyphal transition and therefore in virulence [26, 32].
Plastic-binding proteins
Adherence of C. albicans to plastic medical devices (medical implants,
prostheses and catheters) allows the organism to propagate and establish biofilms;
release of microorganisms from these biofilms contributes to or initiates acute dis-
Acta Microbiologica et Immunologica Hungarica 54, 2007
208 MISHRA et al.
seminated nosocomial infections [9, 33]. Several components of the microfibrillar
surface layer of C. albicans were implicated in plastic binding and plastic adher-
ence appears to be mediated by CSH through hydrophobic bonds between plastic
surfaces and the peptide moieties of the mannoproteins; these mannoproteins may
play other significant roles in cell physiology rather than specifically bind to plas-
tic surfaces. Salivary proteins, adsorbed to plastic material of dental or voice pros-
theses may also help their colonization by fungal cells [30, 34, 35].
Mannan adhesins and other polysaccharides
The mannan portion of mannoproteins may be involved in the fungus – host
interaction. There is evidence indicating that distinct mannan epitopes are compo-
nents of candidal adhesin activity involved in adhesion to epithelial and endothe-
lial surfaces [9, 27, 28]. Mannan also binds to human red blood cells and causes
hemolysis, an activity that may be associated with the ability of the organism to
utilize hemoglobin and iron [36]. Mannan adhesin activity also participates in ad-
herence to salivary components, and interaction with bacteria other than Strepto-
coccal species may involve lectin-like molecules interacting with candidal surface
carbohydrate [9, 34]. O-linked mannose residues of the 58 kDa fibrinogen binding
protein mediates binding to its ligand [29] and, in addition, differential man-
nosylation of cell wall proteins appears to control CSH [30]. Lectin-like receptors
were found on macrophage membranes. A similar mannose receptor and man-
nose-binding lectins and a glucan receptor, dectin-1, are involved in phagocytosis
and cytokine production [31]. PLM also serves as a ligand for Toll-like receptor
(TLR) 4 on the surface of phagocytic cells [32]. Further, several observations indi-
cate that chitin may play a role in adherence to epithelial surfaces, and although
chitin can be exposed at the cell surface at early stages of growth, the role of chitin
in natural infections is uncertain [27].
Other binding proteins
Several C. albicans cell surface mannoproteins interact with fibrinogen, as
well as with other ligands (laminin and C3d), suggesting their relationship to
mammalian integrins [9, 26, 27]. The best characterized fibrinogen receptor is a
58 kDa mannoprotein that appears to interact with fibrinogen through its O-linked
oligosaccharide domain. The ability of C. albicans to bind to fibrinogen may rep-
resent a virulence factor, as coagulation proteins such as fibrin appear to be the re-
ceptor for fungal cell adhesion to blood clots in vivo, and disseminated
intravascular coagulation may lead to severe Candida septicemia. Besides, bind-
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ing of C. albicans cells to platelets appears to be mediated by fibrinogen.
C. albicans cells also bind to plasminogen, although no plasminogen activators
have been detected in C. albicans; several plasminogen-binding proteins have
been isolated from fungal cell walls and binding is not mediated by mannan moi-
eties but appears to involve predominantly C-terminal lysine residues [33]. Acti-
vation of fungal-bound plasminogen by mammalian activators may potentially in-
crease the capacity of the fungus for tissue invasion and necrosis.
The ALS (agglutinin-like sequence) gene family of C. albicans encodes cell
surface glycoproteins (Als) implicated in adhesion to host surfaces [34]. ALS pro-
teins and the structurally related adhesin HWP1 are members of the GPI-depend-
ent cell wall proteins [35], containing N-terminal signal peptides and C-terminal
features mediating GPI membrane anchor addition and other domains leading to
attachment to cell wall glucan. ALS proteins adhere to several host ligands
(laminin, fibronectin, collagen and others) probably by recognizing patches of
certain amino acids (threonine, serine or alanine) [36]. HWP1 is a substrate for ep-
ithelial transglutaminase, a mammalian activator that contributes to the attach-
ment of fungal cells to epithelial surfaces through covalent linkages [37]. Some of
these adhesins, in addition to their role in virulence, also play significant roles in
C. albicans physiology such as dimorphic transition and mating [38, 39].
Immunologic response to cell wall components
Fungal cell wall components play an essential role in triggering and modu-
lating the natural and adaptive anti-Candida host immune responses [10, 31, 40].
Some of the most relevant aspects concerning host immune response and cell wall
components are summarized below. Cell wall PLM has been identified as the
candidal component that stimulates cytokine production by acting as a ligand for
TLR4 [32], a member of the TLR family of evolutionarily conserved trans-
membrane proteins that are the main pattern recognition receptors on the surface
of phagocytic cells and function as sensors of infection that induce innate and
adaptive immune responses [31, 41, 42]. Phagocytosis of C. albicans cells also in-
volves recognition of fungal cells by host receptors, such as the mannose receptor
and lectin-binding proteins and dectin-1, which recognize oligomannosides and
b-glucan as their ligands, respectively [31]. C. albicans cell wall-associated com-
ponents or secreted proteins are fungal antigens that include all potential elicitors
of immunoprotective antibody responses [10].
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Among the immunodominant components there are glycolytic enzymes
(enolase, GAPDH, PGK, ADH) and heat shock proteins (HSP90 and its 47 kDa
heat stable breakdown product, and members of the Hsp70 family), as well as
other mannoproteins considered as virulence factors (SAP, ISM p43). Also
non-protein components show antigenic and immunomodulatory properties, such
as mannan, b-1,2-linked oligomannosides and glucan [10, 43]. Inspite of the in-
creasing awareness of the crucial role of cell-mediated immunity in the defense
against C. albicans infections, only a few antigen targets for it have been so far
been identified [44–46]. These include members of the HSP family, enolase and a
number of mannoproteins, including some with adhesin properties. One of the
best characterized antigen target of the anti-Candida human T-cell response is
Mp65p, a 65 kDa highly glycoslylated protein, which is an immunodominant anti-
gen present in both the cell wall and secreted mannoprotein material. Mp65p is
recognized by T-cells of healthy individuals, and represents a major target of
anti-candidal cell-mediated immunity in humans [46–47]. The amino acid motif
sequence of Mp65p representing the minimal epitope recognized by T-cell clones
has been identified, although the mannan moiety is also probably involved in
T-cell recognition by C. albicans.
Biofilm and candidiasis
Most manifestations of candidiasis are in fact associated with the formation
of Candida biofilms on surfaces, and this phenotype is associated with infection at
both the mucosal and systemic sites [48]. Biofilms are universal, complex, inter-
dependent communities of surface-associated microorganisms. The organisms are
enclosed in an exopolysaccharide occurring on any surface, particularly aquatic
and industrial water systems as well as medical devices. Most microorganisms
grow in structured biofilms rather than individually in suspension and while in this
environment they may display altered phenotypes [49]. Biofilms can be composed
of a population developed from a single species or of a community derived from
multiple microbial species [50, 51]. Speculations about the ecologic advantages of
forming a biofilm include protection from the environment, nutrient availability,
metabolic cooperation and acquisition of new genetic traits [51, 52]. Biofilms are
notoriously difficult to eliminate and are a source of many recalcitrant infections
[53, 54]. A variety of microbial infections is caused by biofilms ranging from uri-
nary tract infections, catheter infections, child middle-ear infections and dental
plaque to more threatening infections such as endocarditis and infections of heart
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valves [54, 55]. Immunocompromised patients such as those with cancer or HIV
infection are often the most susceptible ones.
The mechanisms of biofilm resistance to antimicrobial agents are not yet
fully understood. Bacterial biofilms and their role in disease have been investi-
gated in detail over a number of years, still much less is, however, known about
fungal biofilms. Candida biofilms share several properties with the bacterial ones.
The possible mechanisms include:
Restricted penetration of drugs through the biofilm matrix
It has long been supposed that the matrix of extracellular polymeric mate-
rial might exclude or limit the access of drugs to organisms residing deep in a
biofilm. Most studies with bacterial biofilms indicate that the matrix does not form
a major barrier to drug diffusion, although for certain compounds penetration may
be delayed [56]. To investigate whether the matrix plays a role in the resistance of
C. albicans biofilms to antifungal agents, susceptibility profiles of biofilms incu-
bated statically (which have relatively little matrix) were compared to those incu-
bated under gentle shaking (which produce much more matrix material). Biofilms
grown with or without shaking failed to exhibit significant differences in suscepti-
bility to any of the drugs tested, indicating that drug resistance is unrelated to the
extent of matrix formation [57]. However, separate studies with biofilms pro-
duced under flow conditions showed that resuspended cells (which presumably
had lost most of their matrix) were some 20% less resistant to amphotericin B than
intact biofilms, suggesting that the matrix might play just a minor role in drug re-
sistance [58, 59].
Slow growth rate or nutrient limitation
Biofilm cells are thought to grow slowly because of the limited availability
of nutrients, particularly at the base of the biofilm. A slow growth rate is often ac-
companied by changes in cell surface composition that could, in turn, affect the
susceptibility of the microorganisms to antimicrobial agents. Growth rate could
therefore be an important modulator of drug activity in biofilms [56, 60]. To inves-
tigate this possibility with C. albicans, a perfused biofilm fermenter was used to
generate biofilms at different growth rates and the susceptibility of the biofilm
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cells to amphotericin B was compared to that of planktonic organisms grown at the
same growth rate in a chemostat. The results showed that biofilms were resistant
to the drug at all growth rates tested, whereas planktonic cells were resistant only
at low growth rates [59]. Biofilm resistance is therefore not only the result of a low
growth rate but depends also on some other factors of growth of the biofilm. A
separate study [58] using the cylindrical cellulose filter model system demon-
strated that glucose-limited and iron-limited biofilms grown at the same low rate
were equally resistant to amphotericin B. Iron-limited biofilms probably resemble
more closely those growing in vivo, as although there is an abundance of iron in
the human body, most of it is located intracellularly or tightly complexed to
iron-binding glycoproteins and therefore it is relatively inaccessible to microor-
ganisms. In the same study, daughter cells from iron limited biofilms were signifi-
cantly more susceptible to the drug [58]. An acute disseminated infection pro-
duced by the release of such cells from an implanted biofilm might therefore re-
spond rapidly to amphotericin B while the biofilm itself would remain unaffected.
Surface-induced expression of resistance genes
When microorganisms attach to a surface and form a biofilm they express
an altered phenotype. There have been efforts to identify genes that are activated
or repressed in Candida biofilms compared with planktonic cells, and genes that
might contribute to drug resistance are of particular interest. For example,
upregulation of genes coding for multidrug efflux pumps would result in a
multidrug-resistant phenotype. To date, evidence for this as a resistance mecha-
nism in bacterial biofilms is equivocal [61, 62]. C. albicans possesses two differ-
ent types of efflux pumps: ATP-binding cassette (ABC) transporters and major fa-
cilitators, which are encoded by CDR and MDR genes, respectively. A recent
study has demonstrated that genes encoding both types of efflux pumps are
upregulated during biofilm formation and development. However, mutants carry-
ing single or double deletion mutations in some of these genes were found to be
highly susceptible to fluconazole when growing planktonically but still retained
the resistant phenotype during biofilm growth [63]. These results strongly suggest
that drug resistance in C. albicans biofilms, similar to bacterial biofilms, is a com-
plex process that cannot be explained by a single molecular mechanism.
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Mechanism of drug resistance
Antifungal drug resistance
Many different types of mechanisms are known to contribute to a drug-re-
sistant phenotype in eukaryotic cells. The antifungals which are commonly used
to treat Candida infections and their mechanism of action are listed in Table II.
The different sites of action for the antifungals is cited in Figure 1. The most fre-
quent resistance mechanisms include reduction in the import of the drug into the
cell; modification or degradation of the drug once it is inside the cell; changes in
the interaction of the drug with the target enzyme (binding, activity); changes in
other enzymes of the same enzymatic pathway and an increased efflux of the drug
from the cell [64].
It is important to note that alterations in drug processing (modification or
degradation) are important drug resistance mechanisms in a variety of bacterial
and eukaryotic systems [65]. To date, little analysis of drug modification or degra-
dation within a resistant cell has been performed for the medically important
fungi. It has been mentioned that azoles are inert to metabolism in C. albicans
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CELL WALL SYNTHESIS
Polyoxins
Nikkomycins
Echinocandins
ERGOSTEROL
SYNTHESIS
Azoles
Allylamines
Thiocarbamates
Morpholines
NUCLEAR DIVISION
Griseofulvin
Benomyl
Benzimidazoles
PROTEIN SYNTHESIS
Blasticidin
Sinefungin
MEMBRANE FUNCTION
Polyenes
Amphotericin
Nystatin
Primaricin
METABOLIC
INHIBITORS
Cispentacin
Difluoromethyl
5-Fluorocytosine
Trimethoprim
Sulfomethaxozole
Pentamidine
Ornithine
NUCLEIC ACID
FUNCTION AND
SYNTHESIS
Figure 1. Different sites of action of antifungal agents
[66], although no studies yet have analyzed the sensitivity of azole drugs to metab-
olism in resistant strains or non-albicans species.
Studies on fungi have usually used labeled drugs to monitor the amount of
drug that accumulates within the cell over several minutes. These accumulation
studies have led to the identification of several fungal drug efflux mechanisms.
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Table II
Drugs used against Candida and their mechanism of action
Drugs Mechanism of action
INHIBITORS OF ERGOSTEROL
BIOSYNTHESIS
ALLYLAMINES
e.g. Naftitine and terbinafine
THIOCARBAMATES
e.g. Tolnaftate and tolcitate
AZOLES
e.g. Imidazole (ketoconazole
and miconazole)
e.g. Triazoles (fluconazole,
intraconazole and voriconazole)
PYRIDINES
e.g. Buthiobate and pyrifenox
PYRIMIDINES
e.g. Triarimol and fenarimol
MORPHOLINES
e.g. Fenopropimoph and
amorolfine
OTHER ANTIFUNGAL DRUGS
POLYENES
e.g. Nystatin, amphotericin B
(AmB) and primaricin
5-FLUCYTOSINE (5-FC)
Both allylamines and thiocarbamates inhibit the conversion
of squalene to 2,3-oxidosqualene by the enzyme squalene
expoxidase (which is a product of ERGI gene) leading to ac-
cumulation of squalene in the cells.
Azoles inhibit cytochrome P450 dependent 14a-lanosterol
demethylase (encoded by ERG11) resulting in the accumula-
tion of 14a-methylated sterols, which are toxic to the cells.
Pyridines and pyrimidines also inhibit lanosterol
demethylase and are used in agriculture but not in medicine.
Inhibit D14-reductase and D8–D–7 isomers.
These polyenes intercalate into plasma membranes contain-
ing ergosterol and forms the channel through which cellular
components like potassium ions, leak out and destroy the
proton gradient within the membrane.
Inside the cell, flucytosine is deaminated to 5-fluorouracil
(5-FU). 5-FU is converted into 5-fluorouridine
monophosphate (5-FUMP), and 5-fluoro-deoxyuridine
monophosphate (5-FdUMP). 5-FUMP is incorporated in
RNA, thus disrupting protein synthesis of fungus.
One study with C. albicans suggested that accumulation of [3H] ketoconazole re-
quired glycolytically derived energy and was controlled by cell viability, environ-
mental pH and temperature [67]. This study also showed that ketoconazole accu-
mulation at low extracellular concentrations was saturable, implying a specific fa-
cilitator of import, while accumulation at high concentrations appeared to be by
passive diffusion. Curiously, this study found no evidence for export, since the ad-
dition of unlabeled drug did not lower the concentration of labeled drug in the
cells. Finally, data in this study suggested that other azole drugs and amphotericin
B increased the accumulation of labeled ketoconazole in the cell [67]. The energy
requirement for ketoconazole accumulation described in this study is inconsistent
with the energy-requiring efflux mechanisms. Reduction of energy levels would
inhibit energy-dependent efflux pumps, resulting in increased drug accumulation,
the opposite is seen with ketoconazole. These results suggest that active transport
may be involved in ketoconazole import. It is possible that the ketoconazole and
fluconazole are imported by two different mechanisms.
Another common mechanism of drug resistance is modification of the tar-
get enzyme and/or other enzymes in the same biochemical pathway. The ergos-
terol biosynthetic pathway is one such important target for azole drugs. Analysis
of the sterols in a yeast cell can provide a wealth of information concerning the al-
terations that might have occurred in a resistant strain (Table I). Modifications in
the ergosterol pathway are likely to generate resistance not only to the drug to
which the cells are exposed but also to other related drugs.
A defective lanosterol demethylase (the predominant azole target enzyme)
will result in the accumulation of 14a-methyl sterols, especially 14a-methyl
fecosterol and the diol 14-methyl-ergosta-8, 24(28)-dien-3b, 6a-diol [68, 69]. In
azole-treated cells, the presence of 14a-methyl sterols can modify the function
and fluidity of the plasma membrane. In addition, it appears that cells with
14a-methyl sterols have an increased sensitivity to oxygen-dependent micro-
bicidal systems of the host [70]. The accumulating toxic diol is known to cause
growth arrest in Saccharomyces cerevisiae [69, 71] but is thought to be tolerated
in C. albicans [72]. The toxic effects of the diol in S. cerevisiae are eliminated by a
mutation in ERG3, encoding C-5 sterol desaturase [69, 72, 73].
Plasmid complementation of the ERG3 mutation in S. cerevisiae suggests
that the ERG3 mutation alone can cause azole resistance [69, 74]. Biochemical
analysis suggests that ERG3 mutations are responsible for resistance in at least
two clinical isolates of C. albicans [75]. Also the analysis of sterol composition of
Cryptococcus neoformans revealed that when cells were exposed to itraconazole
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[76], there was an altered sterol composition since the drug affects both lanosterol
demethylase and the C-4 sterol demethylase enzyme, 3-ketosteroid reductase.
The analysis of cell extracts from fungi has been important in monitoring
overall sterol synthesis and the level of inhibition of lanosterol demethylase by
azole drugs [77–79]. For example, cell extracts from a polyene- and azole-resis-
tant strain of C. albicans (D10) did not contain any detectable lanosterol de-
methylase activity whereas the revertant strain, D10R, has lanosterol demethylase
activity [80]. In the absence of the drug, strain D10 accumulates 14a-methyl ster-
ols similar to an azole-treated wild-type cell. Strain D10 is also defective in the
formation of hyphae, while the revertant forms hyphae at normal rates. This find-
ing suggests that hyphal formation, which is an important virulence factor [81] can
be affected by changes in the ergosterol pathway. This has also been found true for
A. fumigatus [82].
The predominant target enzyme of the azole drugs is lanosterol deme-
thylase. The gene encoding this protein is currently designated ERG11 in all fun-
gal species, although it has previously been referred to as ERG16 and CYP51A1 in
C. albicans. Several genetic alterations were identified associated with the ERG11
gene of C. albicans, including point mutations in the coding region, over-
expression of the gene, gene amplification (which leads to overexpression) and
gene conversion or mitotic recombination.
Point mutations in ERG11 were developed in laboratory strains that result
in azole resistance. The point mutation T315A (the replacement of threonine [T]
with alanine [A] at position 315) was constructed in the C. albicans ERG11 gene
[78] based on the current understanding of the active site of the enzyme [83]. The
active site represents a pocket positioned on the top of the heme cofactor. Sub-
strates or inhibitors enter the active site through a channel accessible only with a
shift in a-helix of the apoprotein.
Mutations in the active-site pocket, in the channel and/or in the mobile he-
lix affect the function of the enzyme. The T315A mutation, situated in the ac-
tive-site pocket, was studied in S. cerevisiae, which is more amenable to genetic
manipulation. T315A causes a reduction in the enzymatic activity and a reduction
in azole binding to the active site, resulting in fluconazole resistance. Another
point mutation was identified in the S. cerevisiae ERG11 gene from a laboratory
strain resistant to azole drugs [84, 85]. This mutation, D310G (replacement of as-
partic acid [D] with glycine [G] at position 310), is located in the active site of the
enzyme in close proximity to the T315A mutation and renders the enzyme inac-
tive. However, the azole resistance of this strain is likely due to an ERG3 suppres-
sor rather than to an inactive ERG11 gene product [69].
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A survey of resistant and sensitive clinical isolates has identified seven dif-
ferent point mutations associated with azole-resistant isolates [86]. However, the
matched sensitive isolate was not available from these resistant isolates, which
could be used to determine if the point mutations were associated with resistance
or just the result of allelic variation. ERG11 gene from a variety of fungal sources
was expressed and manipulated in S. cerevisiae [78, 87, 88] and in Escherichia
coli [89]. A recent study used functional expression in S. cerevisiae to identify and
characterize five ERG11 point mutations from matched sets of sensitive and resis-
tant isolates of C. albicans [90]. Overexpression of ERG11 was described in sev-
eral different clinical isolates [91–93). In each case, the level of overexpression is
not substantial (less than a factor of 5). It is difficult to assess the contribution of
ERG11 overexpression to a resistant phenotype, since these limited cases of
overexpression were always accompanied by other alterations associated with re-
sistance, including the R467K mutation, and overexpression of genes regulating
efflux pumps. Overexpression was not extensively evaluated, so it is difficult to
assess its importance. It should be noted that low-level overexpression was also
documented in strains of S. cerevisiae [94–97]. In each case, the effect of
overexpression on antifungal susceptibility was minimal. It remains to be seen if
overexpression of ERG11 alone can result in azole resistance.
Another genetic alteration associated with ERG11 was described in the
same clinical isolates in which the R467K mutation was described [98]. Most, if
not all, strains of C. albicans are diploid, having two alleles of each gene [99].
Clinical isolates are usually clonal [100] and contain several sequence differences
between the two copies of a gene (allelic differences). While analyzing the R467K
mutation, it was observed that all of the allelic differences present in the sensitive
isolate were eliminated in the resistant isolates containing R467K. These allelic
differences were eliminated from the region of the ERG11 gene including the pro-
moter, coding region, and terminator region and into the THR1 gene immediately
downstream of the ERG11 gene [98]. The simplest explanation is that the allelic
differences were eliminated by a gene conversion or mitotic recombination in-
volving the ERG11 gene, although other possibilities (gene or chromosome dele-
tion or mating) could not be completely excluded. This gene conversion or mitotic
recombination resulted in a cell in which both copies of the ERG11 gene contain
the R467K mutation.
In addition to alterations in the lanosterol demethylase, a common mecha-
nism of resistance is an alteration in other enzymes in the same biosynthetic path-
way. Most of the genes of the ergosterol biosynthetic pathway shown in Table III
were cloned in S. cerevisiae [101, 102, 103]. To date, ERG1, ERG2, ERG3, ERG4,
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ERG7, and ERG11 were cloned from C. albicans [104], ERG3 and ERG11 were
cloned from C. glabrata [105, 106], and ERG11 was cloned from C. krusei [105]
and C. tropicalis [107]. In addition, PRD1, the NADPH-cytochrome P-450
reductase important for the function of ERG11, was cloned from C. albicans
[104].
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Table III
Ergosterol biosynthetic pathway from squalene to ergosterol
Enzyme Gene Farnesyl Antifungal
pyrophosphate inhibitors
Squalene synthase ERG9 
SQUALENE
Squalene epoxidase ERG1  Allylamines/
2,3-OXIDOSQUALENE Thiocarbamates
Lanosterol synthase ERG7
Lanosterol 14a- demethylase  Azoles
4,4-DIMETHYL-CHOLESTA
-8,14,24-TRIENOL
C-14 sterol reductase ERG24  Morpholines
14-DIMETHYL LANOSTEROL
C-4 methyl oxidase ERG25 
4-METHYL ZYMOSTEROL
C-4 decarboxylase ERG26 
ZYMOSTEROL
C-24 sterol methyltransferase ERG6  Tomatidine
FECOSTEROL
C-8 sterol isomerase ERG2  Morpholines
EPISTEROL
C-5 sterol desaturase ERG3  Azoles
ERGOSTA-5,7,24(28)-TRIENOL
C-22 sterol desaturase ERG5 
ERGOSTA-5,7,22,24(29)
-TETRAENOL
C-24 sterol desaturase ERG4 
ERGOSTEROL
The antifungal resistance patterns are not similar, suggesting that the pat-
tern of sterol control and antifungal resistance differs between the closely related
yeast species [106]. This suggests that analysis of the ergosterol biosynthetic path-
way in one species may not be applicable to other yeasts. Sterol analysis of
C. albicans clinical isolates suggested that alterations in ERG3 may be a major
cause of azole resistance [108, 109]. ERG3 defects prevent the production of the
diol that would cause growth arrest. ERG3 defects have been suggested to be a ma-
jor source of azole resistance in a number of fungi, including the plant pathogen
U. maydis [110]. In Cryptococcus neoformans, the azoles appear to block directly
or indirectly the C-4 sterol demethylase enzyme complex, preventing the produc-
tion of the diol without an ERG3 defect [111]. Sterol analysis of fluconazole resis-
tance in C. neoformans suggested that resistant strains may have defects in ERG2
or in ERG3 [112]; these strains appear to be crossresistant to amphotericin B. In
addition to its interactions with lanosterol demethylase, itraconazole interacts
with ERG24 in C. neoformans and H. capsulatum, which explains the increased
potency of itraconazole against these species [113].
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Figure 2. Erg3p mediated production of toxic intermediate
Drug efflux and uptake
ABC (ATP-binding cassette) transporters
C. albicans, clinical resistance to fluconazole as a result of reduced
intracellular accumulation was reported for other pathogenic Candida species in-
cluding C. tropicalis, C. glabrata, C. krusei and C. dubliniensis. The azole resis-
tant isolates of Candida cells mainly overexpress genes encoding multidrug efflux
transporter proteins belonging to two superfamilies, the ABC transporters and
MFS [114].
ABC proteins are generally made up of two transmembrane domains
(TMDs) and two cytoplasmically located nucleotide binding domains (NBDs), al-
though ‘half proteins’ that probably dimerize for full functionality are known in
some prokaryotes [115]. Typically, the TMDs comprise a-helices of 12 trans-
membrane segments (TMS) while the NBDs have a-helices and b-sheets arranged
to form a Rossman-fold architecture [115]. While it appears that several TMSs as-
sociate together to form the substrate binding site(s), this alone is probably not suf-
ficient for substrate transport across the membrane bilayer. Cdr1p was the first
ABC transporter identified as a drug efflux pump of C. albicans [116], the gene
encoding a CDR1 was cloned by functional complementation of the S. cerevisiae
pdr5 mutant exhibiting hypersensitivity to cycloheximide and other drugs. Cdr1p
is a close homologue of the ABC transporter human MDR1/P-gp. To date, Cdr1p
and Cdr2p, which are very close homologues, represent two major extrusion
pumps of C. albicans. These pump proteins eliminate not only azoles and its de-
rivatives but also extrudes a variety of structurally unrelated compounds. Other
homologues of CDR1 and CDR2, namely CDR3 and CDR4, were identified but
neither overexpression nor deletion of CDR3 or CDR4 genes affect drug suscepti-
bilities of C. albicans [117]. Cannon's group has found allelic variation in a num-
ber of genes involved in fungal drug resistance [118]. Considering the widely ob-
served polyphormism of human P-gp/MDR1 [119] the characterization of an
allelic variation of drug extrusion proteins of Candida represents an interesting
possibility, which may also contribute to azole resistance. This definitely needs to
be examined to assess if allelic variation in MDR genes of Candida have any clini-
cal relevance. The reported glucose induced phosphorylation of CgCdr1p and
Pdh1p, drug efflux proteins of C. glabrata suggests that posttranslational modifi-
cation of efflux proteins could represent yet another novel mechanism of drug re-
sistance [120].
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Another important characteristic feature of ABC drug transporters is that
they utilize the energy of ATP hydrolysis to transport a variety of substrates across
the plasma membrane. The conserved NBDs located at the cytoplasmic periphery
are the hub of such an activity. The NBDs of all ABC transporters, irrespective of
their origin and the nature of the transport substrate, share extensive amino acid
sequence identity and typical motifs [121]. For example, NBDs of ABC transport-
ers have a b-sheet sub-domain containing the typical Walker A and Walker B mo-
tifs, as an essential feature of all ATP requiring enzymes [122], along with an
a-helical sub-domain that possesses the conserved ABC signature sequence. NBD
protein sequences possess certain conserved amino acid stretches, which are con-
sidered to be critical for the domain’s functionality [123]. These include; the
Walker A, with a consensus sequence GxxGxGKS/T, where ‘x’ represents any
amino acid, the Walker B motif, i.e. hhhhD, where ‘h’ represents any aliphatic res-
idue, and an ABC signature, LSGGQQ/R/KQR. Structural and biochemical anal-
yses of NBDs show that the lysine residue of Walker A motif binds to the b- and
g-phosphates of ribonucleotides and plays a critical role in ATP hydrolysis [123].
Mutation of this lysine residue was shown to reduce or abolish the hydrolytic ac-
tivity and in some cases impairs nucleotide binding [123]. Jha and coworkers
found that an evolutionarily divergent Cys193 of the Walker A motif of NBD1
was critical for ATP hydrolysis. In a recent in vivo study, the relative contribution
of both the N- and C-terminal NBDs in ATP binding, hydrolysis and transporter
activity of native Cdr1p (full protein) was examined wherein the atypical Cys193
of the Walker A motif of NBD1 (C193K) and conserved Lys901 (K901C) in the
Walker A motif of NBD2 were replaced [124]. The drug resistance profile of the
Cdr1p mutant variant cells harboring C193K or K901C gave interesting insights
into the functioning of the two NBDs.
During the ATP hydrolysis step, substrate binding site(s) formed by the
TMDs of the protein favor dissociation rather than association of the drug sub-
strate [125]. While similar information does not yet exist for fungal ABC trans-
porters, it is possible to speculate that such a mechanism operates also in these pro-
teins. Exactly how drug binding is transduced to the NBDs as a signal is however
poorly understood as yet. It is to note that the well-documented drug stimulated
ATPase activity of mammalian ABC transporters has not been found for fungal
transporters [126, 127]. Nevertheless, it is certain that a very close interaction ex-
ists between the TMDs and the NBDs in ABC transporters. For example, it is ob-
served that mutations or deletions in small discrete regions adjacent to the Walker
B motif of P-gp, result in loss of this signaling and therefore of substrate transport
[128].
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Interestingly, NBDs from several ABC transporters supposedly undergo
significant conformational changes due to ATP binding rather than to its hydroly-
sis [129, 130]. This has also been shown to be the case for isolated NBD1 from the
fungal ABC transporter, Cdr1p. Thus catalytically deficient NBD1 variants (with
C193A or D327A/N) continue to exhibit conformational changes similar to wild
type NBD1 while the binding deficient mutant (with W326A) appears to be im-
paired in its ability to perform a similar conformational transition.
MFS efflux pump
MFS proteins are another class of major drug transporters involved in drug
efflux thus, have a role in the multidrug resistance phenomenon displayed by
yeasts. The MFS was originally defined as a superfamily of permeases character-
ized by two structural units of six TMS-a-helical segments, linked by a cytoplas-
mic loop. It is to note that out of several MFS proteins listed in Candida-database
(http://genolist.pasteur.fr/CandidaDB) CaMDR1, its alleles and FLU1 are shown
to be the only drug transporters. CaMDR1 was initially identified as a gene, con-
ferring resistance to the tubulin binding agent benomyl and tetrahydrofolate
reductase inhibitor methotrexate [131, 132]. CaMDR1 expression in S. cerevisiae
confers resistance to several unrelated drugs and its overexpression was linked to
azole resistance in C. albicans. The expression of CaMDR1 in C. albicans cells is
enhanced by benomyl, methotrexate and several other unrelated drugs, and is
found to be more pronounced in some of the azole resistant clinical isolates [133,
134]. Morschhauser and his group employed a proteomic approach to understand
the molecular basis of drug resistance in C. albicans [135]. By comparing the pro-
tein expression pattern of matched pairs of fluconazole resistant and susceptible
clinical isolates, they identified several proteins whose expression was
upregulated specifically when only CaMDR1 gene was overexpressed. These pro-
teins, mostly belonging to putative aldo-keto reductase family were not
upregulated in a fluconazole resistant strain that overexpressed only CDR1/CDR2
and not CaMDR1. This implied that the expression of efflux pump encoding genes
was controlled by different regulatory networks [135].
Recently FLU1, another gene encoding MFS protein of C. albicans was
cloned by complementing strain of S. cerevisiae, which was hypersensitive to
fluconazole. FLU1 is, however, not involved in the development of fluconazole
resistance in clinical isolates of C. albicans. Interestingly, studies revealed that the
preferred substrate of Flu1p is mycophenolic acid rather than fluconazole. Al-
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though more than two dozens of putative MFS genes are identified in the Candida
genome, except for CaMdr1p none of the other proteins of this MFS superfamily
are reported to have any direct role in clinical fluconazole resistance.
Drug uptake
Defects in drug uptake are a common mechanism of drug resistance. How-
ever, it is important to emphasize the distinction between the uptake of a drug into
a cell and the gradual accumulation of the drug in the cell, which is the result of a
balance between uptake into the cell and efflux of the drug from the cell. Analysis
of drug uptake is difficult and requires that mechanisms of uptake be separated
from efflux mechanisms. The hydrophobic nature of drugs permits their easy im-
port by passive diffusion. However, the contribution of drug import to the overall
scenario of MDR is not well established since technically it has not been possible
to separate efflux of drugs from their uptake. Nonetheless, there are few studies
particularly with mammalian cells in which passive diffusion drugs through a lipid
bilayer was shown to be an important determinant of MDR [136]. The variations
in membrane fluidity are expected to affect passive diffusion of drugs and in turn,
their sensitivity to these drugs.
The enhanced fluidity has been linked to enhanced passive diffusion of
drugs [137]. There are factors other than membrane fluidity, that can also influ-
ence diffusion of drugs across the membrane bilayer and thus can affect drug sus-
ceptibilities [138]. The uptake of drugs and its impact on drug resistance needs to
be analyzed more carefully. It is expected that with better experimental designs,
the contribution of import of drugs in MDR can be established.
Risk factors associated with drug resistance
Risk factors associated with fungaemia due to fluconazole-resistant
Candida species have also been studied in non HIV-infected patients. Short case
series of primary fluconazole resistance were reported in patients with severe
neutropenia [139, 140]. Candidaemia due to C. krusei was associated with prior
exposure to fluconazole [141–143]. In one of the largest cases reported, series of
haematogenous C. krusei isolates obtained from a single hospital, it was found that
in addition to prior exposure to fluconazole, acute leukaemia and severe
neutropenia were risk factors for acquiring infections due to this yeast [144]. In-
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fections caused by C. glabrata have also been associated with previous therapy
with amphotericin B, with other antibiotics, permanent central venous catheters,
haemodialysis, abdominal portal of entry and solid tumours [142, 143, 145]. Al-
though an association between fluconazole use and an increase in bloodstream in-
fections due to non-albicans species, including C. glabrata, was reported [143],
some studies reported a reduction in prevalence of C. glabrata and C. krusei after
the introduction of fluconazole prophylaxis.
In a retrospective case, series candidaemia by C. glabrata was seen in a
wide range of patients with different medical conditions and predisposing factors.
In this study, the greatest part of cases came from the intensive care unit and only
very few were neutropenic [145]. A surveillance study of candidaemia in cancer
patients done by the European Organization for Research and Treatment of Can-
cer (EORTC), found that candidaemia by C. glabrata was much more frequent in
patients with haematological malignancies than in those with solid tumors [146].
With regard to moulds, invasive infections due to Fusarium species were de-
scribed in patients with haematological malignancies, severe and prolonged
neutropenia and prior treatment with broad-spectrum antibiotics [147, 148]. Simi-
lar risk factors were identified in deep mycosis caused by S. prolificans [149, 150].
Nearly all patients the Spanish series of S. prolificans infections had acute leukae-
mia [149]. Disease disseminated by A. terreus differed from other species of
Aspergillus in that most of the patients infected with this fungus had a diagnosis of
leukaemia as underlying disease and they were more likely to be neutropenic and
to have a more prolonged neutropenia than patients infected with other Asper-
gillus species [151].
Future scope for strategies to overcome antifungal resistance
The increasing importance of antifungal resistance underlines the need for
developing strategies to clear this problem before it spreads and reaches the rates
of antibacterial drug resistance [152]. Potential mechanisms to overcome fungal
resistance ranges from the synthesis of new drugs with better antifungal activity
and pharmacokinetic profile to improve current therapeutic strategies with
antifungal agents. In addition, antifungal-control programmes to avoid extensive
and inappropriate use of antifungals in hospital and community settings may be
needed [153]. As is the case with antibacterial drug resistance, appropriate use of
antifungals may be critical to delay and in many cases prevent the emergence of
antifungal drug resistance. Given the association between antifungal exposure and
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the development of resistance, prophylaxis should ideally be restricted to care-
fully selected high-risk patients. There should be agreed protocols available for
the use of antifungals as empiric or pre-emptive therapy, to make a more critical
selection of candidates for reducing unnecessary antimicrobial pressure on fungal
pathogens. Another factor that could influence the emergence of resistance is the
dose of drug used for antifungal therapy. Theoretically, treatments with sufficient
drug doses might avoid the development of resistance in less-susceptible fungi.
Thus, the use of high rather than low doses of antifungals may be another potential
measure to avoid and/or to fight against antifungal resistance. In fact, higher than
usual doses of amphotericin B have already been recommended by the Infectious
Diseases Society of America for treating candidaemia caused by C. glabrata and
C. krusei [154]. Nevertheless, the possibility of emergence of highly resistant or-
ganisms under the increased selective pressure should also be considered. Poten-
tial strategies to fight against antifungal resistance include the use of several phar-
macological and non-pharmacological measures.
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